Skip to main content
. Author manuscript; available in PMC: 2021 Aug 13.
Published in final edited form as: J Alzheimers Dis. 2019;67(1):1–11. doi: 10.3233/JAD-180874

Fig. 3.

Fig. 3.

Chemical structures of FDA-approved drugs that potentially can be re-purposed to target neuronal cell cycle re-entry in AD. A) Inhibitors of mTOR. B) Inhibitor of Src family kinases. C) Inhibitor of Ras. D) Inhibitors of Cdk4/6. E) Inhibitor of NMDA receptor. F) Tanimoto analysis of the two-dimensional similarity of the chemical structures of potential regulators of CCR. 1) Memantine. 2) Saracatinib. 3) Abemaciclib. 4) Palbociclib. 5) Ribociclib. 6) Salirasib. 7) Rapamycin. 8) Temsirolimus. 9) Everolimus. Tanimoto analysis was performed with PubChem software (https://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?p=clustering).